LT3370733T - Cd40 aktyvinimo ir imuninės kontrolės taškų blokados būdai - Google Patents
Cd40 aktyvinimo ir imuninės kontrolės taškų blokados būdaiInfo
- Publication number
- LT3370733T LT3370733T LTEPPCT/US2016/059996T LT16059996T LT3370733T LT 3370733 T LT3370733 T LT 3370733T LT 16059996 T LT16059996 T LT 16059996T LT 3370733 T LT3370733 T LT 3370733T
- Authority
- LT
- Lithuania
- Prior art keywords
- activation
- blocking
- methods
- control points
- immune control
- Prior art date
Links
- 101150013553 CD40 gene Proteins 0.000 title 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 title 1
- 230000004913 activation Effects 0.000 title 1
- 230000000903 blocking effect Effects 0.000 title 1
Classifications
-
- G—PHYSICS
- G08—SIGNALLING
- G08G—TRAFFIC CONTROL SYSTEMS
- G08G1/00—Traffic control systems for road vehicles
- G08G1/14—Traffic control systems for road vehicles indicating individual free spaces in parking areas
- G08G1/141—Traffic control systems for road vehicles indicating individual free spaces in parking areas with means giving the indication of available parking spaces
- G08G1/144—Traffic control systems for road vehicles indicating individual free spaces in parking areas with means giving the indication of available parking spaces on portable or mobile units, e.g. personal digital assistant [PDA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- G—PHYSICS
- G08—SIGNALLING
- G08G—TRAFFIC CONTROL SYSTEMS
- G08G1/00—Traffic control systems for road vehicles
- G08G1/01—Detecting movement of traffic to be counted or controlled
- G08G1/0104—Measuring and analyzing of parameters relative to traffic conditions
- G08G1/0108—Measuring and analyzing of parameters relative to traffic conditions based on the source of data
- G08G1/0112—Measuring and analyzing of parameters relative to traffic conditions based on the source of data from the vehicle, e.g. floating car data [FCD]
-
- G—PHYSICS
- G08—SIGNALLING
- G08G—TRAFFIC CONTROL SYSTEMS
- G08G1/00—Traffic control systems for road vehicles
- G08G1/01—Detecting movement of traffic to be counted or controlled
- G08G1/0104—Measuring and analyzing of parameters relative to traffic conditions
- G08G1/0125—Traffic data processing
- G08G1/0129—Traffic data processing for creating historical data or processing based on historical data
-
- G—PHYSICS
- G08—SIGNALLING
- G08G—TRAFFIC CONTROL SYSTEMS
- G08G1/00—Traffic control systems for road vehicles
- G08G1/01—Detecting movement of traffic to be counted or controlled
- G08G1/0104—Measuring and analyzing of parameters relative to traffic conditions
- G08G1/0137—Measuring and analyzing of parameters relative to traffic conditions for specific applications
- G08G1/0141—Measuring and analyzing of parameters relative to traffic conditions for specific applications for traffic information dissemination
-
- G—PHYSICS
- G08—SIGNALLING
- G08G—TRAFFIC CONTROL SYSTEMS
- G08G1/00—Traffic control systems for road vehicles
- G08G1/14—Traffic control systems for road vehicles indicating individual free spaces in parking areas
- G08G1/145—Traffic control systems for road vehicles indicating individual free spaces in parking areas where the indication depends on the parking areas
- G08G1/147—Traffic control systems for road vehicles indicating individual free spaces in parking areas where the indication depends on the parking areas where the parking area is within an open public zone, e.g. city centre
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
- H04L67/00—Network arrangements or protocols for supporting network services or applications
- H04L67/01—Protocols
- H04L67/02—Protocols based on web technology, e.g. hypertext transfer protocol [HTTP]
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04W—WIRELESS COMMUNICATION NETWORKS
- H04W4/00—Services specially adapted for wireless communication networks; Facilities therefor
- H04W4/02—Services making use of location information
- H04W4/023—Services making use of location information using mutual or relative location information between multiple location based services [LBS] targets or of distance thresholds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/52—CD40, CD40-ligand (CD154)
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
- H04L67/00—Network arrangements or protocols for supporting network services or applications
- H04L67/2866—Architectures; Arrangements
- H04L67/30—Profiles
- H04L67/306—User profiles
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Signal Processing (AREA)
- Computer Networks & Wireless Communication (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562249725P | 2015-11-02 | 2015-11-02 | |
PCT/US2016/059996 WO2017079202A1 (en) | 2015-11-02 | 2016-11-02 | Methods of cd40 activation and immune checkpoint blockade |
Publications (1)
Publication Number | Publication Date |
---|---|
LT3370733T true LT3370733T (lt) | 2021-10-25 |
Family
ID=58662649
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LTEPPCT/US2016/059996T LT3370733T (lt) | 2015-11-02 | 2016-11-02 | Cd40 aktyvinimo ir imuninės kontrolės taškų blokados būdai |
Country Status (6)
Country | Link |
---|---|
US (2) | US11594135B2 (lt) |
EP (1) | EP3370733B1 (lt) |
ES (1) | ES2892972T3 (lt) |
LT (1) | LT3370733T (lt) |
SI (1) | SI3370733T1 (lt) |
WO (1) | WO2017079202A1 (lt) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11298420B2 (en) * | 2016-12-21 | 2022-04-12 | Memgen, Llc | Armed oncolytic viruses |
AU2017379835A1 (en) * | 2016-12-21 | 2019-07-11 | Dnatrix | Armed replication-competent oncolytic adenoviruses |
US12171803B2 (en) | 2017-04-12 | 2024-12-24 | Memgen, Inc. | Methods of CD40 and toll like receptor immune activation |
EP3768316A4 (en) * | 2018-03-23 | 2022-06-01 | The University Of Western Australia | METHODS OF IMMUNOTHERAPEUTIC DRUG TREATMENT |
US11250363B2 (en) | 2018-11-02 | 2022-02-15 | Cornell University | Resource allocation using scalable non-myopic atomic game for smart parking and other applications |
WO2022056302A1 (en) * | 2020-09-11 | 2022-03-17 | Memgen, Inc. | Enhancing immunity using chimeric cd40 ligand and coronavirus vaccine |
EP4308175A4 (en) * | 2021-03-16 | 2025-02-26 | H Lee Moffitt Cancer Center & Res Institute Inc | TIL ENHANCEMENT BY EX VIVO STIMULATION WITH CD40 AGONISTS |
US11756311B2 (en) * | 2021-05-18 | 2023-09-12 | Toyota Motor Engineering & Manufacturing North America, Inc. | Parking spot and person detection |
Family Cites Families (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4797368A (en) | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
US5302523A (en) | 1989-06-21 | 1994-04-12 | Zeneca Limited | Transformation of plant cells |
US5550318A (en) | 1990-04-17 | 1996-08-27 | Dekalb Genetics Corporation | Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof |
US7705215B1 (en) | 1990-04-17 | 2010-04-27 | Dekalb Genetics Corporation | Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof |
US5322783A (en) | 1989-10-17 | 1994-06-21 | Pioneer Hi-Bred International, Inc. | Soybean transformation by microparticle bombardment |
US5484956A (en) | 1990-01-22 | 1996-01-16 | Dekalb Genetics Corporation | Fertile transgenic Zea mays plant comprising heterologous DNA encoding Bacillus thuringiensis endotoxin |
US5384253A (en) | 1990-12-28 | 1995-01-24 | Dekalb Genetics Corporation | Genetic transformation of maize cells by electroporation of cells pretreated with pectin degrading enzymes |
US6410010B1 (en) | 1992-10-13 | 2002-06-25 | Board Of Regents, The University Of Texas System | Recombinant P53 adenovirus compositions |
US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
WO1993004169A1 (en) | 1991-08-20 | 1993-03-04 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
US5610042A (en) | 1991-10-07 | 1997-03-11 | Ciba-Geigy Corporation | Methods for stable transformation of wheat |
US5716805A (en) | 1991-10-25 | 1998-02-10 | Immunex Corporation | Methods of preparing soluble, oligomeric proteins |
US5641670A (en) | 1991-11-05 | 1997-06-24 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
DE69334225D1 (de) | 1992-07-07 | 2008-07-31 | Japan Tobacco Inc | Verfahren zur transformation einer monokotyledon pflanze |
US5702932A (en) | 1992-07-20 | 1997-12-30 | University Of Florida | Microinjection methods to transform arthropods with exogenous DNA |
CA2140910C (en) | 1992-07-27 | 1999-03-23 | Jeffrey A. Townsend | An improved method of agrobacterium-mediated transformation of cultured soybean cells |
DE4228457A1 (de) | 1992-08-27 | 1994-04-28 | Beiersdorf Ag | Herstellung von heterodimerem PDGF-AB mit Hilfe eines bicistronischen Vektorsystems in Säugerzellen |
US5540926A (en) | 1992-09-04 | 1996-07-30 | Bristol-Myers Squibb Company | Soluble and its use in B cell stimulation |
GB9222888D0 (en) | 1992-10-30 | 1992-12-16 | British Tech Group | Tomography |
JP4242447B2 (ja) | 1993-01-22 | 2009-03-25 | イミュネックス・コーポレーション | Cd40リガンド遺伝子の突然変異の検出および治療 |
AU7326594A (en) | 1993-07-09 | 1995-02-06 | Synergen, Inc. | Recombinant ctla4 polypeptides and methods for making the same |
US5656610A (en) | 1994-06-21 | 1997-08-12 | University Of Southern California | Producing a protein in a mammal by injection of a DNA-sequence into the tongue |
FR2722208B1 (fr) | 1994-07-05 | 1996-10-04 | Inst Nat Sante Rech Med | Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique |
US5736524A (en) | 1994-11-14 | 1998-04-07 | Merck & Co.,. Inc. | Polynucleotide tuberculosis vaccine |
US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
US5780448A (en) | 1995-11-07 | 1998-07-14 | Ottawa Civic Hospital Loeb Research | DNA-based vaccination of fish |
US5928906A (en) | 1996-05-09 | 1999-07-27 | Sequenom, Inc. | Process for direct sequencing during template amplification |
US5844905A (en) | 1996-07-09 | 1998-12-01 | International Business Machines Corporation | Extensions to distributed MAC protocols with collision avoidance using RTS/CTS exchange |
US5945100A (en) | 1996-07-31 | 1999-08-31 | Fbp Corporation | Tumor delivery vehicles |
JP4203835B2 (ja) | 1996-08-19 | 2009-01-07 | アメリカ合衆国 | 全身への送達を増加させる新規のリポソーム複合体 |
US5981274A (en) | 1996-09-18 | 1999-11-09 | Tyrrell; D. Lorne J. | Recombinant hepatitis virus vectors |
JP2001523958A (ja) | 1997-03-21 | 2001-11-27 | ブライハム アンド ウィミンズ ホスピタル,インコーポレイテッド | 免疫療法のctla−4結合ペプチド |
US5994624A (en) | 1997-10-20 | 1999-11-30 | Cotton Incorporated | In planta method for the production of transgenic plants |
US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
BR9916853A (pt) | 1998-12-23 | 2001-11-20 | Pfizer | Anticorpos monoclonais humanos ao ctla-4 |
US7605238B2 (en) * | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
CA2589418A1 (en) | 1999-08-24 | 2001-03-01 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
US6482411B1 (en) | 1999-08-27 | 2002-11-19 | Board Of Regents, The University Of Texas System | Methods of reducing bone loss with CD40 ligand |
US6961912B2 (en) * | 2001-07-18 | 2005-11-01 | Xerox Corporation | Feedback mechanism for use with visual selection methods |
US7495090B2 (en) | 2002-05-23 | 2009-02-24 | The Regents Of The University Of California | Nucleic acids encoding chimeric CD154 polypeptides |
US7105347B2 (en) | 2002-07-30 | 2006-09-12 | Corning Incorporated | Method and device for protein delivery into cells |
US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
US8008449B2 (en) | 2005-05-09 | 2011-08-30 | Medarex, Inc. | Human monoclonal antibodies to programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
US8068627B2 (en) | 2006-03-14 | 2011-11-29 | Starkey Laboratories, Inc. | System for automatic reception enhancement of hearing assistance devices |
US20080318886A1 (en) * | 2006-12-05 | 2008-12-25 | Prussak Charles E | Methods of Increasing Cancer Sensitivity to Chemotherapeutic Agents Using Chimeric ISF35 |
WO2008141155A1 (en) | 2007-05-11 | 2008-11-20 | The Board Of Regents Of The University Of Nebraska | Compositions for protein delivery and methods of use thereof |
ME02093B (me) | 2007-06-18 | 2014-04-30 | N V Organon | Antitijela za humani receptor programirane smrti pd-1 |
EP2242773B1 (en) | 2008-02-11 | 2017-06-14 | Cure Tech Ltd. | Monoclonal antibodies for tumor treatment |
US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
JP5264348B2 (ja) | 2008-07-29 | 2013-08-14 | キヤノン株式会社 | 画像処理装置及びその制御方法、コンピュータプログラム及び記憶媒体 |
WO2010014784A2 (en) | 2008-08-01 | 2010-02-04 | Bristol-Myers Squibb Company | Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases |
KR20100020891A (ko) | 2008-08-13 | 2010-02-23 | 삼성전자주식회사 | 광대역 무선통신 시스템에서 고속 피드백 채널을 이용한 정보 송수신 장치 및 방법 |
BRPI0917891A2 (pt) | 2008-08-25 | 2015-11-24 | Amplimmune Inc | antagonistas de pd-1 e métodos de utilização dos mesmos |
EP2498823B1 (en) | 2009-11-13 | 2018-08-29 | INSERM - Institut National de la Santé et de la Recherche Médicale | Direct protein delivery with engineered microvesicles |
US20130017199A1 (en) | 2009-11-24 | 2013-01-17 | AMPLIMMUNE ,Inc. a corporation | Simultaneous inhibition of pd-l1/pd-l2 |
KR101926663B1 (ko) | 2010-02-19 | 2018-12-07 | 젠코어 인코포레이티드 | 신규의 CTLA4-Ig 이뮤노어드헤신 |
US8976655B2 (en) * | 2010-09-16 | 2015-03-10 | Vasona Networks Inc. | Evaluating a capacity of a cell of a radio access network |
CA2856895C (en) * | 2011-11-28 | 2021-10-26 | Merck Patent Gmbh | Anti-pd-l1 antibodies and uses thereof |
CA2877384C (en) | 2012-07-02 | 2023-05-09 | Iprogen Biotech Inc. | Intracellular protein delivery |
JP2014022858A (ja) | 2012-07-17 | 2014-02-03 | Murata Mfg Co Ltd | 電力増幅器 |
US20150231241A1 (en) | 2012-08-14 | 2015-08-20 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
JP6090988B2 (ja) * | 2013-03-05 | 2017-03-08 | 株式会社 日立パワーデバイス | 半導体装置 |
US9308236B2 (en) | 2013-03-15 | 2016-04-12 | Bristol-Myers Squibb Company | Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions |
RU2016107426A (ru) | 2013-08-02 | 2017-09-07 | Адуро Байотек Холдингс, Юроуп Б.В. | Комбинирование агонистов cd27 и ингибирование иммунных контрольных точек для стимуляции иммунитета |
CN107090041B (zh) | 2013-09-13 | 2018-11-16 | 百济神州有限公司 | 抗pd1抗体及其作为治疗剂与诊断剂的用途 |
US9469933B2 (en) * | 2014-05-16 | 2016-10-18 | Whirlpool Corporation | Method and apparatus for using gravity to precisely dose detergent in a washing machine |
WO2017007547A1 (en) * | 2015-07-07 | 2017-01-12 | Codexis, Inc. | Novel p450-bm3 variants with improved activity |
WO2017019896A1 (en) * | 2015-07-29 | 2017-02-02 | Novartis Ag | Combination therapies comprising antibody molecules to pd-1 |
WO2017079297A1 (en) * | 2015-11-02 | 2017-05-11 | Memgen Llc | Methods for treatment of cancer |
-
2016
- 2016-11-02 LT LTEPPCT/US2016/059996T patent/LT3370733T/lt unknown
- 2016-11-02 WO PCT/US2016/059996 patent/WO2017079202A1/en active Application Filing
- 2016-11-02 EP EP16862825.3A patent/EP3370733B1/en active Active
- 2016-11-02 SI SI201631369T patent/SI3370733T1/sl unknown
- 2016-11-02 ES ES16862825T patent/ES2892972T3/es active Active
- 2016-11-02 US US15/772,789 patent/US11594135B2/en active Active
-
2018
- 2018-09-14 US US16/131,355 patent/US20190057605A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
ES2892972T3 (es) | 2022-02-07 |
US11594135B2 (en) | 2023-02-28 |
WO2017079202A1 (en) | 2017-05-11 |
US20190057605A1 (en) | 2019-02-21 |
US20200165339A1 (en) | 2020-05-28 |
EP3370733B1 (en) | 2021-07-14 |
SI3370733T1 (sl) | 2021-11-30 |
EP3370733A4 (en) | 2019-04-17 |
EP3370733A1 (en) | 2018-09-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1256066A1 (zh) | 熱控設備及其使用方法 | |
LT3872085T (lt) | Viruso prototipo sekos ir jų panaudojimas | |
IL264064B (en) | Hiv pre-immunization and immunotherapy | |
ZA201702562B (en) | Pest control system and method of operating same | |
IL254727A0 (en) | Mice genetically engineered to express signal-regulating protein alpha and interleukin 15 and methods of using them | |
LT3317284T (lt) | Benzoksazepino oksazolidinono junginiai ir jų naudojimo būdai | |
IL249292A0 (en) | Methods and devices for treating pulmonary edema | |
LT3368534T (lt) | Valbenazino ditozilatas ir jo polimorfai | |
LT3280441T (lt) | Anti-sortilino antikūnai ir jų naudojimo būdai | |
LT3212189T (lt) | Pakeisti chromanai ir naudojimo būdas | |
IL247131A0 (en) | A method for optimizing the arrangement of a target and associated target | |
BR112017002511A2 (pt) | sistemas e métodos de almofada terapêutica | |
LT3370733T (lt) | Cd40 aktyvinimo ir imuninės kontrolės taškų blokados būdai | |
LT3114884T (lt) | Debesų įrenginio identifikavimas ir autentifikavimas | |
LT3331877T (lt) | Pirazolpirimidino dariniai ir jų panaudojimas | |
LT3394065T (lt) | Tetrahidropiranilamino-pirolopirimidinonas ir jo panaudojimo būdai | |
LT3341027T (lt) | Transfekcijos kompleksai ir jų panaudojimo būdai | |
LT3200815T (lt) | Būdai ir kompozicijos, skirti vėžio gydymui | |
LT3443010T (lt) | Nauji anti-sirpa antikūnai ir jų terapinio panaudojimo būdai | |
HK1231402A1 (zh) | 治療 型肝炎和 型肝炎病毒感染的方法 | |
BR112018000204A2 (pt) | métodos de tratamento de colite | |
SG10201501819SA (en) | Semiconductor device and control method of the same | |
DK3379942T3 (da) | Temperaturstyret optøningsfremgangsmåde og -apparat | |
LT3220937T (lt) | Pneumolizino mutantai ir jų naudojimo būdai | |
PL3565374T3 (pl) | Sposoby i urządzenia do konfiguracji obszaru |